Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERV trial of palivizumab prophylaxis in otherwise healthy preterm infants
2018-002980-25Phase 3Active
- Sponsor
- ASL Biella
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palivizumab in respiratory syncytial virus disease (RSV) and bronchiolitis (2 arms), sponsored by ASL Biella. Primary endpoint: Overall respiratory morbidity. Started Oct 2020; status: active.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)bronchiolitis
Beyond the preview
Go deeper on 2018-002980-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002980-25.